CAMBRIDGE, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceuticals company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced that Biogen Idec Inc. (Nasdaq: BIIB) has submitted an Investigational New Drug (IND) application for BIIB015. This event triggers a $1.5 million milestone payment to ImmunoGen. BIIB015 comprises ImmunoGen’s cell-killing agent, DM4, linked to Biogen Idec’s Cripto-targeting antibody, and is in development by Biogen Idec for the treatment of solid tumors that express the Cripto antigen.
